Bristol-Myers Squibb
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Bristol-Myers Squibb sits in the top decile of US sponsors by registered trial count (#32 of 15,742 sponsors by registered trial count).
Bristol-Myers Squibb: 1,025 sponsored US clinical trials, 73 recruiting.
Bristol-Myers Squibb sponsors 1,025 registered US clinical trials on ClinicalTrials.gov, 73 of them currently recruiting, and 789 completed. 242 of these trials are in Phase 3-4 (later-stage) and 675 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 20 trials.
Top-decile sponsor footprint
Bristol-Myers Squibb ranks in the top decile of sponsors by registered trial count (#32 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
789 of 892 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,025 total, page 21 of 21
Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
NCT00306878
A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.
NCT00002349
A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs
NCT00002308
Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients
NCT00002041
A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia
NCT00002067
A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
NCT00002369
A Study of Lobucavir in Patients With AIDS
NCT00002352
The Safety and Effectiveness of Megace in HIV-Infected Women
NCT00002345
A Study of Different Doses of Megestrol Acetate in Patients With AIDS Who Have Anorexia and Malnutrition
NCT00002300
A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers
NCT00002261
A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)
NCT00002028
Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine
NCT00002035
A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine
NCT00002280
Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer
NCT00103831
Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC
NCT00002057
A Comparison of Zidovudine (AZT) and Stavudine in HIV-Infected Patients
NCT00002307
Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis
NCT00279760
A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes
NCT00002293
A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine
NCT00002274
A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients
NCT00002168
A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV
NCT00002358
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
NCT00002418
Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer
NCT00099879
A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy
NCT00036621
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
NCT00002420
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 436 |
| Phase 2 | 239 |
| Phase 3 | 213 |
| Phase 4 | 29 |
Therapeutic Areas
What is open in the Bristol-Myers Squibb pipeline
73 recruiting of 1,025 indexed (7% open); 789 completed (77%).
Phase mix: 242 late (III/IV) vs 675 early (I/II) (early-phase heavy).
Top condition: HIV Infections (20 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bristol-Myers Squibb: open-pipeline peers nationwide
Peers matched on 1,025 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Bristol-Myers Squibb sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,025 trials (± recruiting share)
- University of Wisconsin, Madison · 1,039 trials · 15% recruiting
- University of Washington · 1,048 trials · 15% recruiting
- University of Minnesota · 966 trials · 19% recruiting
- Columbia University · 958 trials · 18% recruiting
Sponsors near 7% open enrollment (± trial volume)
- Carol Fabian, MD · 7% recruiting · 14 trials
- Celldex Therapeutics · 7% recruiting · 42 trials
- Kaiser Permanente · 7% recruiting · 294 trials
- Mannkind Corporation · 7% recruiting · 42 trials
Related
What to do with this Bristol-Myers Squibb page
1,025 registered trials is a research-attention snapshot, not an endorsement of Bristol-Myers Squibb or any single study.
- 73 of Bristol-Myers Squibb's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition Bristol-Myers Squibb studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Bristol-Myers Squibb pipeline card: 1,025 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.